63 related articles for article (PubMed ID: 20018410)
1. Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration.
Shin M; Jan C; Jacquard C; Jarraya B; Callebert J; Launay JM; Hantraye P; Remy P; Palfi S; Brouillet E
Neurobiol Aging; 2011 Nov; 32(11):2100-2. PubMed ID: 20018410
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.
Mathur BN; Neely MD; Dyllick-Brenzinger M; Tandon A; Deutch AY
Brain Res; 2007 Sep; 1168():83-9. PubMed ID: 17706185
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons.
Schapira AH; Cleeter MW; Muddle JR; Workman JM; Cooper JM; King RH
Ann Neurol; 2006 Aug; 60(2):253-5. PubMed ID: 16862591
[TBL] [Abstract][Full Text] [Related]
4. The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Oct; 1354():236-42. PubMed ID: 20678493
[TBL] [Abstract][Full Text] [Related]
5. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB
Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664
[TBL] [Abstract][Full Text] [Related]
6. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
7. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice.
Li X; Yin J; Cheng CM; Sun JL; Li Z; Wu YL
Chin Med J (Engl); 2005 Aug; 118(16):1357-61. PubMed ID: 16157030
[TBL] [Abstract][Full Text] [Related]
8. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
9. Lack of nigrostriatal pathology in a rat model of proteasome inhibition.
Manning-Boğ AB; Reaney SH; Chou VP; Johnston LC; McCormack AL; Johnston J; Langston JW; Di Monte DA
Ann Neurol; 2006 Aug; 60(2):256-60. PubMed ID: 16862576
[TBL] [Abstract][Full Text] [Related]
10. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
11. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
12. Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice.
Ren JP; Zhao YW; Sun XJ
Chin Med J (Engl); 2009 Oct; 122(19):2366-71. PubMed ID: 20079141
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Landau AM; Kouassi E; Siegrist-Johnstone R; Desbarats J
Mov Disord; 2007 Feb; 22(3):403-7. PubMed ID: 17230468
[TBL] [Abstract][Full Text] [Related]
14. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.
Kordower JH; Kanaan NM; Chu Y; Suresh Babu R; Stansell J; Terpstra BT; Sortwell CE; Steece-Collier K; Collier TJ
Ann Neurol; 2006 Aug; 60(2):264-8. PubMed ID: 16862579
[TBL] [Abstract][Full Text] [Related]
15. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
16. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
17. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Gao L; Díaz-Martín J; Dillmann WH; López-Barneo J
Neuroscience; 2011 Oct; 193():323-9. PubMed ID: 21782904
[TBL] [Abstract][Full Text] [Related]
19. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
[TBL] [Abstract][Full Text] [Related]
20. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
